GlassScriptPhysician profile
Shruti Badhwar
NPI 1497918502
$22,361.17
in general payments reported to CMS, 2019-2025
44 companies · $587 in 2025
The $587 reported for 2025 was more than what a typical Clinical Neurophysiology provider received nationally (typical 2025 total: $435).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,669 · 2020: $5,769 · 2021: $10K · 2022: $2,344 · 2023: $1,775 · 2024: $150 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,513.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,513.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $11,389.32 | 2020-2021 | |
| Sk Life Science, INC. | $3,195.64 | 2020-2021 | |
| Ucb, INC. | $1,276.19 | 2019-2024 | Briviact |
| Abbvie INC. | $828.79 | 2021-2025 | Ubrelvy, Botox, Qulipta |
| Livanova USA, INC. | $638.88 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $508.95 | 2019-2023 | |
| Emd Serono, INC. | $464.18 | 2019-2024 | Mavenclad |
| Lilly USA, LLC | $415.84 | 2019-2025 | Kisunla, Reyvow, Emgality |
| Biogen, INC. | $399.98 | 2019-2025 | Vumerity |
| Sunovion Pharmaceuticals INC. | $341.99 | 2019-2022 | |
| Amgen INC. | $309.52 | 2019-2023 | Aimovig |
| Supernus Pharmaceuticals, INC. | $264.75 | 2019-2020 | |
| Neuropace, INC. | $201.34 | 2022-2025 | |
| Impel Pharmaceuticals INC. | $169.57 | 2022-2023 | Trudhesa |
| Pfizer INC. | $168.22 | 2025 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shruti Badhwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.